Table 1.
Demographic characteristics of the patients in our study group.
| Parameter | Mild CSU (n = 69) |
Moderate/Severe CSU (n = 149) | p | |
|---|---|---|---|---|
| Age * | 38.05 ± 6.2 | 59.89 ± 9.7 | 0.01 | |
| Sex | male | 34.7% (24) | 20.1% (30) | 0.2 |
| female | 65.3% (65) | 79.9% (99) | ||
| Living area | urban | 78.2% (54) | 68.4% (102) | 0.7 |
| rural | 21.8% (15) | 31.6% (27) | ||
| CSU onset (months) | 124 (3–160) | 186 (4.5–268) | 0.5 | |
| CSU scores | UAS7 | ≤15 | ≥16 | 0.01 |
| VAS | ≤6 | ≥6 | 0.01 | |
| Treatment | AH1 | 10% (7) | 2.6% (4) | 0.05 |
| 2xAH1 | 37.6% (26) | 5.9% (10) | 0.8 | |
| 4xAH1 | 37.6% (26) | 36.2% (54) | 0.05 | |
| * Omalizumab | 0% (0) | 16.7% (25) | 0.01 | |
| * Cyclosporine | 0% (0) | 2% (3) | 0.01 | |
| * Prednisone | 0% (0) | 22.1% (33) | 0.01 | |
| CSU in remission | No treatment | 21.8% (15) | 16.7% (25) | 0.6 |
| COVID 19 infection | Not present | 69.5% (48) | 65.7% (98) | 0.7 |
| Present | 31.5% (21) | 34.3% (51) | 0.8 | |
* Data are expressed as mean ± SD. Significance p < 0.05.